SecBot SecBot
SECBOTREPLAY Home › Report › NSPR

NSPR · FDA approves CGuard Prime TCAR

InspireMD Inc. · PRESS-RELEASE filed Nov 12, 2026 at 16:03 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Nov 12, 2026 at 16:03 ET

InspireMD reported Q3 2026 revenue of $2.24M, below the $2.0M consensus, and a GAAP net loss of $0.12 per share, narrower than the consensus loss of $0.15. The headline is the FDA approval of CGuard Prime for TCAR procedures, which expands the U.S. addressable market by over 35,000 procedures annually and enables a U.S. commercial re-entry in Q4 2026. However, total revenue fell 11% YoY due to the voluntary recall of the CGuard Prime for CAS delivery system, and the company's cash position dropped to $19.2M from $54.2M at year-end 2025, raising liquidity concerns.

  • FDA approval of CGuard Prime for TCAR procedures, expanding U.S. addressable market by over 35,000 procedures annually
  • Q3 2026 total revenue $2.24M, down 11.1% YoY from $2.52M
  • Q3 2026 GAAP net loss $0.12 per share vs $0.17 loss in Q3 2025
  • International revenue $2.21M, up 9.1% YoY; U.S. revenue $32,000 vs $497,000 due to recall

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access